EGFR and non-small cell lung carcinoma: Currently, the front-line treatment landscape for advanced NSCLC harboring EGFR mutations is becoming increasingly congested, leading to treatment decisions more complex.280 Beyond the goal of extending survival, treatment recommendations should be personalized to strike a balance between the risk of increased toxicity from novel therapies and their potential benefits.